Assessment of an immature platelet fraction (IPF) in peripheral thrombocytopenia
Assessment of an immature platelet fraction (IPF) in peripheral thrombocytopenia
复制标题
DOI：
10.1111/j.1365-2141.2004.04987.x
复制
发表时间：
2004-07-01
影响因子：
6.5
通讯作者：
Machin, SJ
中科院分区：
文献类型：
--
作者：
Briggs, C;Kunka, S;Machin, SJ
利用XE-2100血细胞计数器和升级软件（Sysmex，科比，日本）开发了一种新的自动化方法，用于可靠地定量网织血小板（表示为未成熟血小板分数（IPF））。通过流式细胞术技术和在网织红细胞/光学血小板通道中使用核酸特异性染料鉴定IPF。在实验室诊断由于外周血小板破坏增加引起的血小板减少症，特别是自身免疫性血小板减少性紫癜（AITP）和血栓性血小板减少性紫癜（TTP）中，确立了该参数的临床效用。48 h以上的重现性和稳定性结果良好。健康个体的IPF参考范围确定为1.1- 6.1%，平均值为3.4%。对血小板破坏可能异常的患者进行了研究，其中2例患者在治疗过程中进行了连续随访。IPF在几种疾病状态下升高。在AITP（平均22.3%，范围9.2-33.1%）和急性TTP（平均17.2%，范围11.2-30.9%）患者中发现IPF值增加最显著。治疗期间随访患者表明，随着血小板计数恢复，IPF%下降。这些结果表明，一种快速，廉价的自动化方法来测量IPF%是可行的，并应成为一个标准参数，在评估血小板减少症患者。
A new automated method to reliably quantify reticulated platelets, expressed as the immature platelet fraction (IPF), has been developed utilizing the XE-2100 blood cell counter with upgraded software (Sysmex, Kobe, Japan). The IPF is identified by flow cytometry techniques and the use of a nucleic acid specific dye in the reticulocyte/optical platelet channel. The clinical utility of this parameter was established in the laboratory diagnosis of thrombocytopenia due to increased peripheral platelet destruction, particularly autoimmune thrombocytopenic purpura (AITP) and thrombotic thrombocytopenic purpura (TTP). Reproducibility and stability results over 48 h were good. An IPF reference range in healthy individuals was established as 1.1-6.1%, with a mean of 3.4%. Patients in whom platelet destruction might be abnormal, were studied and two of these patients followed serially during the course of treatment. The IPF was raised in several disease states. The most significant increases in IPF values were found in patients with AITP (mean 22.3%, range 9.2-33.1%) and acute TTP (mean 17.2%, range 11.2-30.9%). Following patients during treatment demonstrated that as the platelet count recovered the IPF% fell. These results show that a rapid, inexpensive automated method for measuring the IPF% is feasible and should become a standard parameter in evaluating the thrombocytopenic patient.